Journal article
Astrocytic activity in treatment-resistant and ultra-treatment-resistant schizophrenia.
Claudia Cicognola, Dhamidhu Eratne, Matthew JY Kang, Shorena Janelidze, Charles B Malpas, Samantha M Loi, Wei-Hsuan Chiu, Cassandra MJ Wannan, Chad Bousman, Ian Everall, Naveen Thomas, Dennis Velakoulis, Christos Pantelis, Alexander F Santillo
Schizophr Res | Elsevier BV | Published : 2026
Abstract
Astrocytic dysfunction has been implicated in schizophrenia, but biomarkers of astrocytic activity have shown inconsistent patterns. Studies on disease heterogeneity, specifically treatment-resistant schizophrenia (TRS) and ultra-treatment-resistant schizophrenia (UTRS) are lacking. In this study, plasma glial fibrillary acidic protein (GFAP) was measured using an ultrasensitive Simoa assay in 174 participants (58 controls, 35 first-degree relatives, and 81 patients with TRS, according to Treatment Response and Resistance in Psychosis (TRRIP) criteria. A further n = 35 fulfilled TRRIP criteria for UTRS. Data included symptom severity, cognition, and functioning assessments. Cortical thicknes..
View full abstractGrants
Awarded by Region Skåne
Awarded by National Health and Medical Research Council